A new clinical trial is set to explore the potential of a specially designed medical tampon to detect the earliest signs of ovarian cancer. The trial, known as **Violet**, will recruit approximately **250 women** across **Southampton**, aiming to revolutionize the way this often late-diagnosed disease is identified. Researchers believe this innovative approach could significantly improve early detection, thereby enhancing treatment outcomes.
The study focuses on women diagnosed with ovarian cancer who are undergoing surgery to remove their ovaries, as well as those with the **BRCA gene mutation**. Individuals with this mutation face a heightened risk of developing various cancers, including ovarian cancer. Currently, the only preventive measure for these women often involves surgery, which can lead to early menopause and long-term health implications.
Dr. Jemma Longley, a consultant medical oncologist at **University Hospital Southampton** and the trial’s chief investigator, emphasized the lack of a screening program for ovarian cancer. “Women with recognized genetic mutations, such as BRCA, may opt to have surgery to reduce their cancer risk. However, this can have significant long-term health effects,” she explained.
Innovative Testing Method
The trial will collect samples of vaginal fluid using the medical tampon and swabs. Researchers will also analyze tissue from the removed ovaries and fallopian tubes, comparing them to samples from women without the disease. The primary focus will be on identifying **microRNAs**, tiny biological signals present in both ovarian cancer cells and vaginal fluid. This analysis could lead to earlier detection of the disease, which is currently diagnosed at an advanced stage in many cases.
In the UK, there are around **7,600 new cases of ovarian cancer** diagnosed each year, but many patients discover their illness when it has already progressed. The diagnostic tampon has been developed by the biotechnology company **Daye**, which aims to provide a less invasive option for early detection.
David Constable-Phelps, a consultant gynaecological oncology surgeon and co-investigator for the study, expressed optimism about the potential findings. “The ability to detect the earliest signs of ovarian cancer with a relatively non-invasive test, such as the Daye tampon, would be a complete game-changer for women,” he stated. The symptoms of ovarian cancer can be vague and non-specific, often leading to a late diagnosis when the cancer has already spread.
Potential Impact on Women’s Health
Athena Lamnisos, chief executive of **The Eve Appeal**, which has funded the study, highlighted the importance of this research for women with altered BRCA genes. “Anyone with an altered BRCA gene faces very difficult decisions around their health and family planning,” she noted. Lamnisos hopes that this research could lead to a straightforward, user-friendly test that provides tailored information to those making health decisions.
“This could help reduce the risk of ovarian cancer development or catch it in its earliest stages when it is most treatable,” she added, reiterating the potential impact of the Violet trial on women’s health.
As the trial progresses, researchers are hopeful that it will pave the way for further studies to deepen the understanding of ovarian cancer biology and enhance early intervention strategies. The outcomes of this trial could not only change the diagnostic landscape for ovarian cancer but also improve the lives of countless women facing this challenging disease.
